Jart Ate Franke Oosterhaven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jart Ate Franke Oosterhaven has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Marie Louise Anna Schuttelaar
Department of Dermatology, University Medical Center Groningen, University of Groningen , Groningen
29 shared publications - Angelique Nadine Voorberg
Department of Dermatology University of Groningen, University Medical Center Groningen Groningen The Netherlands
7 shared publications - Aviël Ragamin
Department of Dermatology, Erasmus MC, University Medical Center , Rotterdam
4 shared publications - Christian Apfelbacher
Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany
4 shared publications Elke Weisshaar
Division of Occupational Dermatology, Department of Dermatology University Hospital Heidelberg Heidelberg Germany
4 shared publicationsGeertruida L. E. Romeijn
Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands
4 shared publications
Latest Publications
- Open Access
- 4 October 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5) , e324-e328
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema Questionnaire
- 4 October 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5) , e324-e328
Open AccessDupilumab improves quality of life assessed by the Quality of Life in Hand Eczema Questionnaire
- Open Access
- 18 February 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv42364
Validation of the Atopic Dermatitis Control Tool (ADCT) and a Comparison with the Recap of Atopic Eczema Questionnaire (RECAP)
The Atopic Dermatitis Control Tool (ADCT) has not been validated in the Dutch population, and comparisons with the Recap of atopic eczema (RECAP) questionnaire are still lacking. This prospective study was conducted at a Dutch tertiary hospital between June 2021 and December 2022, to assess measurement properties of the Dutch ADCT in adults with atopic dermatitis (AD) and compare it with RECAP. Participants completed the ADCT, RECAP, and reference instruments including Patient’s Global Assessment (PtGA), Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), quality-of-life questionnaire of the EuroQol Group (EQ-5D-5L), Numeric Rating Scale (NRS) peak itch/sleep disturbance, Skindex-29, and Global Rating of Change (GRC), at baseline, 1–3 days, and 4–12 weeks. Construct validity was assessed through a priori hypotheses, whilst reliability was evaluated with standard error of measurement (SEMagreement) and intraclass correlation coefficient (ICCagreement). Interpretability was examined using anchor-based approaches. In total, 196 adults with AD were included. Among a priori hypotheses, 82% (single-score validity) and 59% (responsiveness) were confirmed. The SEMagreement was 1.15, and the ICCagreement was 0.983. The final bandings for the ADCT were established, with a binary cutoff of ≥ 6 indicating uncontrolled AD. The smallest detectable change (SDC) was 3.2, and the minimally important change (MIC) value from predictive modelling was 2.9. Furthermore, the ADCT exhibited high correlations with RECAP at all levels (most correlations being above 0.80). These results demonstrated the Dutch ADCT as a valid, reliable, and responsive tool, and have important clinical implications.
- 18 February 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv42364
Open AccessValidation of the Atopic Dermatitis Control Tool (ADCT) and a Comparison with the Recap of Atopic Eczema Questionnaire (RECAP)
The Atopic Dermatitis Control Tool (ADCT) has not been validated in the Dutch population, and comparisons with the Recap of atopic eczema (RECAP) questionnaire are still lacking. This prospective study was conducted at a Dutch tertiary hospital between June 2021 and December 2022, to assess measurement properties of the Dutch ADCT in adults with atopic dermatitis (AD) and compare it with RECAP. Participants completed the ADCT, RECAP, and reference instruments including Patient’s Global Assessment (PtGA), Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), quality-of-life questionnaire of the EuroQol Group (EQ-5D-5L), Numeric Rating Scale (NRS) peak itch/sleep disturbance, Skindex-29, and Global Rating of Change (GRC), at baseline, 1–3 days, and 4–12 weeks. Construct validity was assessed through a priori hypotheses, whilst reliability was evaluated with standard error of measurement (SEMagreement) and intraclass correlation coefficient (ICCagreement). Interpretability was examined using anchor-based approaches. In total, 196 adults with AD were included. Among a priori hypotheses, 82% (single-score validity) and 59% (responsiveness) were confirmed. The SEMagreement was 1.15, and the ICCagreement was 0.983. The final bandings for the ADCT were established, with a binary cutoff of ≥ 6 indicating uncontrolled AD. The smallest detectable change (SDC) was 3.2, and the minimally important change (MIC) value from predictive modelling was 2.9. Furthermore, the ADCT exhibited high correlations with RECAP at all levels (most correlations being above 0.80). These results demonstrated the Dutch ADCT as a valid, reliable, and responsive tool, and have important clinical implications.
- Open Access
- 10 November 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (11) , e70060
Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
Bruton's tyrosine kinase (BTK) is a potential therapeutic target for allergic and autoimmune diseases. This first‐in‐human phase I study evaluated safety, pharmacokinetic, and pharmacodynamic profiles of sofnobrutinib (formerly AS‐0871), a highly selective, orally available, non‐covalent BTK inhibitor, in healthy adult subjects. Single ascending doses (SAD; 5–900 mg) and multiple ascending doses (MAD; 50–300 mg twice daily [b.i.d.] for 14 days [morning dose only on Day 14]) of sofnobrutinib were tested. In the entire study, all adverse events (AEs) were mild or moderate, and no apparent dose‐proportional trend in severity or frequency was observed. No serious treatment‐emergent AEs, cardiac arrythmias, or bleeding‐related AEs were reported. In the SAD part, sofnobrutinib exhibited approximately dose‐dependent systemic exposures up to 900 mg with rapid absorption (median time to maximum concentration of 2.50–4.00 h) and gradual decline (mean half‐lives of 3.7–9.0 h). In the MAD part, sofnobrutinib showed low accumulation after multiple dosing (mean accumulation ratios of ≤1.54) and reached a steady state on ≤Day 7. Single dosing of sofnobrutinib rapidly and dose‐dependently suppressed basophil and B‐cell activations in ex vivo whole blood assays. Multiple dosing of sofnobrutinib achieved 50.8%–79.4%, 67.6%–93.6%, and 90.1%–98.0% inhibition of basophil activation during the dosing interval of 50, 150, and 300 mg b.i.d., respectively. Based on pharmacokinetic‐pharmacodynamic analysis, half‐maximal inhibitory concentration (IC50) of sofnobrutinib for basophil activation was 54.06 and 57.01 ng/mL in the SAD and MAD parts, respectively. Similarly, IC50 for B‐cell activation was 187.21 ng/mL. These data support further investigation of sofnobrutinib in allergic and autoimmune diseases.
- 10 November 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (11) , e70060
Open AccessSafety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
Bruton's tyrosine kinase (BTK) is a potential therapeutic target for allergic and autoimmune diseases. This first‐in‐human phase I study evaluated safety, pharmacokinetic, and pharmacodynamic profiles of sofnobrutinib (formerly AS‐0871), a highly selective, orally available, non‐covalent BTK inhibitor, in healthy adult subjects. Single ascending doses (SAD; 5–900 mg) and multiple ascending doses (MAD; 50–300 mg twice daily [b.i.d.] for 14 days [morning dose only on Day 14]) of sofnobrutinib were tested. In the entire study, all adverse events (AEs) were mild or moderate, and no apparent dose‐proportional trend in severity or frequency was observed. No serious treatment‐emergent AEs, cardiac arrythmias, or bleeding‐related AEs were reported. In the SAD part, sofnobrutinib exhibited approximately dose‐dependent systemic exposures up to 900 mg with rapid absorption (median time to maximum concentration of 2.50–4.00 h) and gradual decline (mean half‐lives of 3.7–9.0 h). In the MAD part, sofnobrutinib showed low accumulation after multiple dosing (mean accumulation ratios of ≤1.54) and reached a steady state on ≤Day 7. Single dosing of sofnobrutinib rapidly and dose‐dependently suppressed basophil and B‐cell activations in ex vivo whole blood assays. Multiple dosing of sofnobrutinib achieved 50.8%–79.4%, 67.6%–93.6%, and 90.1%–98.0% inhibition of basophil activation during the dosing interval of 50, 150, and 300 mg b.i.d., respectively. Based on pharmacokinetic‐pharmacodynamic analysis, half‐maximal inhibitory concentration (IC50) of sofnobrutinib for basophil activation was 54.06 and 57.01 ng/mL in the SAD and MAD parts, respectively. Similarly, IC50 for B‐cell activation was 187.21 ng/mL. These data support further investigation of sofnobrutinib in allergic and autoimmune diseases.
- Open Access
- 23 January 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (6) , 867-875
The construct validity, responsiveness, reliability and interpretability of the Recap of atopic eczema questionnaire (RECAP) in children
The Recap of atopic eczema questionnaire (RECAP) was developed to measure eczema control in patients with atopic dermatitis (AD). Measurement properties of RECAP have not yet been validated in caregivers of children with AD. To assess the construct validity, responsiveness, reliability and interpretability of the Dutch proxy version of RECAP. A prospective validation study was conducted among children (0, Baseline; T1, after 1–7 days; T2, after 4–8 weeks) RECAP and multiple reference instruments were completed by caregivers of children patients. Construct validity: Single and change-score validity (responsiveness) were tested with a priori hypotheses on correlations with reference instruments. Reliability: intraclass correlation coefficients (ICCagreement) and standard error of agreement (SEMagreement) were reported. Interpretability of single scores: Bands for perceived eczema control were proposed. Interpretability of change score: The smallest detectable change (SDC) and minimally important change (MIC) were determined. Two anchor-based methods based on receiver operating characteristic curve (ROC) and predictive modelling were used to determine the MIC. A total of 231 children with AD and their caregivers participated in the study. Of our a prior hypotheses for single-score and change-score validity, 77% and 80% were confirmed, respectively. Stronger correlation than hypothesized was found for all rejected hypotheses. Excellent reliability was found (ICCagreement: 0.94; 95% confidence interval (CI): 0.90-0.96). The SEMagreement was 1.9 points. The final banding was: 0-1 (completely controlled), 2-7 (mostly controlled), 8-12 (moderately controlled), 13-18 (a little controlled), 19-28 (not at all controlled). A cut-off point of ≥8 was selected to identify children whose AD is not under control. The SDC was 5.3 and the MIC value 1.5 and 3.6 for the ROC and predictive modelling approach respectively. No floor or ceiling effects were observed. The proxy version of RECAP is a valid, reliable and responsive measurement instrument for measuring eczema control in children with AD. An improvement of ≥6 points can be regarded as real and important change in children with AD.
- 23 January 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (6) , 867-875
Open AccessThe construct validity, responsiveness, reliability and interpretability of the Recap of atopic eczema questionnaire (RECAP) in children
The Recap of atopic eczema questionnaire (RECAP) was developed to measure eczema control in patients with atopic dermatitis (AD). Measurement properties of RECAP have not yet been validated in caregivers of children with AD. To assess the construct validity, responsiveness, reliability and interpretability of the Dutch proxy version of RECAP. A prospective validation study was conducted among children (0, Baseline; T1, after 1–7 days; T2, after 4–8 weeks) RECAP and multiple reference instruments were completed by caregivers of children patients. Construct validity: Single and change-score validity (responsiveness) were tested with a priori hypotheses on correlations with reference instruments. Reliability: intraclass correlation coefficients (ICCagreement) and standard error of agreement (SEMagreement) were reported. Interpretability of single scores: Bands for perceived eczema control were proposed. Interpretability of change score: The smallest detectable change (SDC) and minimally important change (MIC) were determined. Two anchor-based methods based on receiver operating characteristic curve (ROC) and predictive modelling were used to determine the MIC. A total of 231 children with AD and their caregivers participated in the study. Of our a prior hypotheses for single-score and change-score validity, 77% and 80% were confirmed, respectively. Stronger correlation than hypothesized was found for all rejected hypotheses. Excellent reliability was found (ICCagreement: 0.94; 95% confidence interval (CI): 0.90-0.96). The SEMagreement was 1.9 points. The final banding was: 0-1 (completely controlled), 2-7 (mostly controlled), 8-12 (moderately controlled), 13-18 (a little controlled), 19-28 (not at all controlled). A cut-off point of ≥8 was selected to identify children whose AD is not under control. The SDC was 5.3 and the MIC value 1.5 and 3.6 for the ROC and predictive modelling approach respectively. No floor or ceiling effects were observed. The proxy version of RECAP is a valid, reliable and responsive measurement instrument for measuring eczema control in children with AD. An improvement of ≥6 points can be regarded as real and important change in children with AD.
- Open Access
- 18 July 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (5) , 578-587
Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire
Limited research has been conducted on the measurement properties of the Recap of atopic eczema (RECAP) questionnaire, particularly its interpretability. To investigate the validity, reliability, responsiveness, and interpretability of the Dutch RECAP in adults with atopic dermatitis (AD). We conducted a prospective study in a Dutch tertiary hospital, recruiting adults with AD between June 2021 and December 2022. Patients completed the RECAP questionnaire, reference instruments, and anchor questions at three time points: baseline, after 1-3 days, and after 4-12 weeks. Validity: Hypotheses-testing was used to investigate single-score validity and change-score validity (responsiveness). Reliability: Both standard error of measurement (SEMagreement) and intraclass correlation coefficient (ICCagreement) were reported. Interpretability of single score: Bands for eczema control were proposed. Interpretability of change score: Both smallest detectable change (SDC) and minimally important change (MIC) scores were determined. To estimate the MIC scores, four different anchor-based methods were employed: the mean change method, 95% limit cut-off point, receiver operating characteristic curve, and predictive modelling. In total, 200 participants were included (57.5% male, mean age 38.5 years). Of the a priori hypotheses, 82% (single-score validity) and 59% (responsiveness) were confirmed. Known-group analyses showed differences in the RECAP scores between patient groups based on disease severity and impairment of the quality of life. The SEMagreement was 1.17 points, and the ICCagreement was 0.988. The final banding was: 0-1 (completely controlled); 2-5 (mostly controlled); 6-11 (moderately controlled); 12-19 (a little controlled); 20-28 (not at all controlled). Moreover, a single cut-off point of ≥6 was determined to identify patients whose AD is not under control. The SDC was 3.2 points, and the MIC value from the predictive modeling was 3.9 points. Neither floor nor ceiling effects were seen. The RECAP has good single-score validity, moderate responsiveness and excellent reliability. This study fills a gap in the interpretability of the RECAP. Our results indicate a threshold of ≥6 points to identify patients whose AD is ‘not under control’, while an improvement of ≥4 points represents a clinically important change. Given its endorsement by the Harmonising Outcome Measures for Eczema (HOME) initiatives, the results of this study support the integration of RECAP into both routine clinical practice and research settings.
- 18 July 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (5) , 578-587
Open AccessValidity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire
Limited research has been conducted on the measurement properties of the Recap of atopic eczema (RECAP) questionnaire, particularly its interpretability. To investigate the validity, reliability, responsiveness, and interpretability of the Dutch RECAP in adults with atopic dermatitis (AD). We conducted a prospective study in a Dutch tertiary hospital, recruiting adults with AD between June 2021 and December 2022. Patients completed the RECAP questionnaire, reference instruments, and anchor questions at three time points: baseline, after 1-3 days, and after 4-12 weeks. Validity: Hypotheses-testing was used to investigate single-score validity and change-score validity (responsiveness). Reliability: Both standard error of measurement (SEMagreement) and intraclass correlation coefficient (ICCagreement) were reported. Interpretability of single score: Bands for eczema control were proposed. Interpretability of change score: Both smallest detectable change (SDC) and minimally important change (MIC) scores were determined. To estimate the MIC scores, four different anchor-based methods were employed: the mean change method, 95% limit cut-off point, receiver operating characteristic curve, and predictive modelling. In total, 200 participants were included (57.5% male, mean age 38.5 years). Of the a priori hypotheses, 82% (single-score validity) and 59% (responsiveness) were confirmed. Known-group analyses showed differences in the RECAP scores between patient groups based on disease severity and impairment of the quality of life. The SEMagreement was 1.17 points, and the ICCagreement was 0.988. The final banding was: 0-1 (completely controlled); 2-5 (mostly controlled); 6-11 (moderately controlled); 12-19 (a little controlled); 20-28 (not at all controlled). Moreover, a single cut-off point of ≥6 was determined to identify patients whose AD is not under control. The SDC was 3.2 points, and the MIC value from the predictive modeling was 3.9 points. Neither floor nor ceiling effects were seen. The RECAP has good single-score validity, moderate responsiveness and excellent reliability. This study fills a gap in the interpretability of the RECAP. Our results indicate a threshold of ≥6 points to identify patients whose AD is ‘not under control’, while an improvement of ≥4 points represents a clinically important change. Given its endorsement by the Harmonising Outcome Measures for Eczema (HOME) initiatives, the results of this study support the integration of RECAP into both routine clinical practice and research settings.
- Open Access
- 1 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (6) , 919-926
Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study
Background: Recap of atopic eczema (RECAP) is a patient-reported outcome measure assessing eczema control. This instrument has been developed and validated in the UK. There are self-reported and proxy-reported versions in English, Dutch and German. However, it is unclear whether the self-reported version shows adequate content validity when completed by young people (8–16 years) in these languages. Objectives: To assess the content validity (comprehensibility, relevance and comprehensiveness) of the English, German and Dutch versions of the self-reported RECAP in young people with atopic eczema and to identify the most appropriate age cutoff for self-completion. Methods: We conducted 23 semistructured cognitive interviews with young people aged 8–16 years, using the ‘think-aloud’ method. In Germany and the Netherlands, participants were recruited in dermatology clinics and in the UK through social media and existing mailing lists. Interviews were audio recorded, transcribed verbatim and analysed in the three languages, using a problem-focused coding manual. Transcripts were coded by two independent reviewers in each country. Themes were translated into English and compared across the three countries. Results: Significant age-related comprehensibility issues with the last three items of the questionnaire occurred with young people aged 8–11 years, causing difficulties completing RECAP without help. However, older children had only minor problems and were able to complete the questionnaire by themselves. The self-reported version of RECAP has sufficient content validity for self-completion in young people aged 12 years and above. However, the German version with some translational adaptations may be appropriate for children from the age of 8 years. There may be some situations where the proxy version is needed for older children too. Conclusions: The self-reported version of RECAP is appropriate for use from the age of 12 years. The proxy version can be used in children younger than 12 years. Other measurement properties should be further investigated. What is already known about this topic? Recap of atopic eczema (RECAP) is an instrument recommended by the Harmonising Outcome Measures for Eczema initiative for the core outcome domain of long-term control of atopic eczema.Content validity of RECAP for self-completion by adults and of the proxy version has been assessed. What does this study add? In this study, content validity (comprehensibility, relevance and comprehensiveness) of the self-reported version of RECAP among young people (aged 8–16 years) with atopic eczema across the UK, Germany and the Netherlands is assessed.Based on these findings, key recommendations on how to measure eczema control in young people with atopic eczema are formulated. What are the clinical implications of this work? The Dutch, English and German self-completion versions of RECAP are recommended for use in adolescents from the age of 12 years.The proxy version could be used in children younger than 12 years or where children are cognitively or physically incapable of reporting their experience of eczema control.Caregivers should be encouraged to complete RECAP together with their child where possible.
- 1 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (6) , 919-926
Open AccessContent validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study
Background: Recap of atopic eczema (RECAP) is a patient-reported outcome measure assessing eczema control. This instrument has been developed and validated in the UK. There are self-reported and proxy-reported versions in English, Dutch and German. However, it is unclear whether the self-reported version shows adequate content validity when completed by young people (8–16 years) in these languages. Objectives: To assess the content validity (comprehensibility, relevance and comprehensiveness) of the English, German and Dutch versions of the self-reported RECAP in young people with atopic eczema and to identify the most appropriate age cutoff for self-completion. Methods: We conducted 23 semistructured cognitive interviews with young people aged 8–16 years, using the ‘think-aloud’ method. In Germany and the Netherlands, participants were recruited in dermatology clinics and in the UK through social media and existing mailing lists. Interviews were audio recorded, transcribed verbatim and analysed in the three languages, using a problem-focused coding manual. Transcripts were coded by two independent reviewers in each country. Themes were translated into English and compared across the three countries. Results: Significant age-related comprehensibility issues with the last three items of the questionnaire occurred with young people aged 8–11 years, causing difficulties completing RECAP without help. However, older children had only minor problems and were able to complete the questionnaire by themselves. The self-reported version of RECAP has sufficient content validity for self-completion in young people aged 12 years and above. However, the German version with some translational adaptations may be appropriate for children from the age of 8 years. There may be some situations where the proxy version is needed for older children too. Conclusions: The self-reported version of RECAP is appropriate for use from the age of 12 years. The proxy version can be used in children younger than 12 years. Other measurement properties should be further investigated. What is already known about this topic? Recap of atopic eczema (RECAP) is an instrument recommended by the Harmonising Outcome Measures for Eczema initiative for the core outcome domain of long-term control of atopic eczema.Content validity of RECAP for self-completion by adults and of the proxy version has been assessed. What does this study add? In this study, content validity (comprehensibility, relevance and comprehensiveness) of the self-reported version of RECAP among young people (aged 8–16 years) with atopic eczema across the UK, Germany and the Netherlands is assessed.Based on these findings, key recommendations on how to measure eczema control in young people with atopic eczema are formulated. What are the clinical implications of this work? The Dutch, English and German self-completion versions of RECAP are recommended for use in adolescents from the age of 12 years.The proxy version could be used in children younger than 12 years or where children are cognitively or physically incapable of reporting their experience of eczema control.Caregivers should be encouraged to complete RECAP together with their child where possible.
- Open Access
- 1 June 2022
- Published by Wiley in Contact Dermatitis
- Vol. 87 (4) , 366-368
Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: Results from a prematurely discontinued randomized controlled trial
- 1 June 2022
- Published by Wiley in Contact Dermatitis
- Vol. 87 (4) , 366-368
Open AccessEfficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: Results from a prematurely discontinued randomized controlled trial
- Top Cited Papers
- 30 December 2021
- Published by Wiley in Contact Dermatitis
- Vol. 86 (5) , 357-378
Guidelines for diagnosis, prevention, and treatment of hand eczema
Background: Hand eczema is a common inflammatory skin disorder. Health care providers need continuously updated information about the management of hand eczema to ensure best treatment for their patients.Objectives: To update the European Society of Contact Dermatitis guideline on the diagnosis, prevention, and treatment on of hand eczema.Method: The Guideline Development Group (GDG) was established on behalf of the ESCD. A call for interest was launched via the ESCD website and via the ESCD members' mailing list. Appraisal of the evidence for therapeutic and preventive interventions was applied and a structured method of developing consensus was used and moderated by an external methodologist. The final guideline was approved by the ESCD executive committee and was in external review on the ESCD webpage for 1 month.Results: Consensus was achieved for several statements and management strategies.Conclusion: The updated guideline should improve management of hand eczema.
- 30 December 2021
- Published by Wiley in Contact Dermatitis
- Vol. 86 (5) , 357-378
Top Cited PapersGuidelines for diagnosis, prevention, and treatment of hand eczema
Background: Hand eczema is a common inflammatory skin disorder. Health care providers need continuously updated information about the management of hand eczema to ensure best treatment for their patients.Objectives: To update the European Society of Contact Dermatitis guideline on the diagnosis, prevention, and treatment on of hand eczema.Method: The Guideline Development Group (GDG) was established on behalf of the ESCD. A call for interest was launched via the ESCD website and via the ESCD members' mailing list. Appraisal of the evidence for therapeutic and preventive interventions was applied and a structured method of developing consensus was used and moderated by an external methodologist. The final guideline was approved by the ESCD executive committee and was in external review on the ESCD webpage for 1 month.Results: Consensus was achieved for several statements and management strategies.Conclusion: The updated guideline should improve management of hand eczema.
- Open Access
- 12 July 2021
- Published by Wiley in Experimental Dermatology
- Vol. 30 (12) , 1775-1786
Vesicular hand eczema transcriptome analysis provides insights into its pathophysiology
Hand eczema is a common inflammatory skin condition of the hands whose pathogenesis is largely unknown. More insight and knowledge of the disease on a more fundamental level might lead to a better understanding of the biological processes involved, which could provide possible new treatment strategies. We aimed to profile the transcriptome of lesional palmar epidermal skin of patients suffering from vesicular hand eczema using RNA‐sequencing. RNA‐sequencing was performed to identify differentially expressed genes in lesional vs. non‐lesional palmar epidermal skin from a group of patients with vesicular hand eczema compared to healthy controls. Comprehensive real‐time quantitative PCR analyses and immunohistochemistry were used for validation of candidate genes and protein profiles for vesicular hand eczema. Overall, a significant and high expression of genes/proteins involved in keratinocyte host defense and inflammation was found in lesional skin. Furthermore, we detected several molecules, both up or downregulated in lesional skin, which are involved in epidermal differentiation. Immune signalling genes were found to be upregulated in lesional skin, albeit with relatively low expression levels. Non‐lesional patient skin showed no significant differences compared to healthy control skin. Lesional vesicular hand eczema skin shows a distinct expression profile compared to non‐lesional skin and healthy control skin. Notably, the overall results indicate a large overlap between vesicular hand eczema and earlier reported atopic dermatitis lesional transcriptome profiles, which suggests that treatments for atopic dermatitis could also be effective in (vesicular) hand eczema.
- 12 July 2021
- Published by Wiley in Experimental Dermatology
- Vol. 30 (12) , 1775-1786
Open AccessVesicular hand eczema transcriptome analysis provides insights into its pathophysiology
Hand eczema is a common inflammatory skin condition of the hands whose pathogenesis is largely unknown. More insight and knowledge of the disease on a more fundamental level might lead to a better understanding of the biological processes involved, which could provide possible new treatment strategies. We aimed to profile the transcriptome of lesional palmar epidermal skin of patients suffering from vesicular hand eczema using RNA‐sequencing. RNA‐sequencing was performed to identify differentially expressed genes in lesional vs. non‐lesional palmar epidermal skin from a group of patients with vesicular hand eczema compared to healthy controls. Comprehensive real‐time quantitative PCR analyses and immunohistochemistry were used for validation of candidate genes and protein profiles for vesicular hand eczema. Overall, a significant and high expression of genes/proteins involved in keratinocyte host defense and inflammation was found in lesional skin. Furthermore, we detected several molecules, both up or downregulated in lesional skin, which are involved in epidermal differentiation. Immune signalling genes were found to be upregulated in lesional skin, albeit with relatively low expression levels. Non‐lesional patient skin showed no significant differences compared to healthy control skin. Lesional vesicular hand eczema skin shows a distinct expression profile compared to non‐lesional skin and healthy control skin. Notably, the overall results indicate a large overlap between vesicular hand eczema and earlier reported atopic dermatitis lesional transcriptome profiles, which suggests that treatments for atopic dermatitis could also be effective in (vesicular) hand eczema.
- Open Access
- 21 June 2021
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (4) , 1986-1989
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry
Eczema control is a new construct to be measured in atopic dermatitis (AD).Measuring patient-perceived eczema control and treatment satisfaction in AD patients, treated with dupilumab between 16 an...
- 21 June 2021
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (4) , 1986-1989
Open AccessEczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry
Eczema control is a new construct to be measured in atopic dermatitis (AD).Measuring patient-perceived eczema control and treatment satisfaction in AD patients, treated with dupilumab between 16 an...